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with tumorigenesis markers BMI1, MCM4
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Abstract
Background: Carbonic anhydrase IX (CA9) is a transmembrane glycoprotein related to hypoxia. Increased CA9
expression has been associated with decreased survival and cancer progression and has been targeted as a potential
therapy for several cancers, including esophageal cancer. The reported percentages of expression of CA9 in esophageal
adenocarcinoma vary, and CA9 expression in precancerous esophageal lesions has not been well studied.
Methods: In this study, we investigated CA9 expression in esophageal cancers and in precancerous lesions and
explored the association of CA9 expression with prognostic factors and with stem cell and tumorigenesis-related markers
including BMI1, cyclin E, ki67, MCM4 and MCM7 expression. Previously constructed tissue microarrays consisting
of samples of 7 tissue types (columnar cell metaplasia, Barrett esophagus, low- and high-grade dysplasia, esophageal
adenocarcinoma, squamous epithelium, and squamous cell carcinoma) were used for the immunostaining of CA9,
BMI1, cyclin E, Ki67, MCM4 and MCM7.
Results and discussion: CA9 high expression occurred more frequently in glandular mucosa with or without dysplasia
than in squamous epithelium or squamous cell carcinoma. Survival duration of esophageal adenocarcinoma did not
significantly differ between patients with high CA9 expression and those with low expression. High CA9 expression is
significantly associated with BMI1, cyclin E, Ki67, MCM4 and MCM7 expression.
Conclusions: High CA9 expression may be related to the acidic environment caused by gastroesophageal reflux
disease in the gastroesophageal junction and associated with tumorigenesis through BMI1, MCM4 and MCM7.
Keywords: CA9, Esophageal adenocarcinoma, Esophageal squamous cell carcinoma, Barrett’s esophagus,
Gastroesophageal reflux disease, BMI1
Background
The incidence of esophageal adenocarcinoma in the
United States has increased dramatically, by over 600 %,
in the past few decades [1–3]. Esophageal adenocarcin-
oma is an aggressive disease that has a poor prognosis,
with an overall 5-year survival rate of approximately
17 % in the United States [2]. Barrett esophagus is char-
acterized by metaplasia when goblet cells replace the
normal squamous epithelium of the esophagus; it is a
precancerous lesion that can lead to esophageal adeno-
carcinoma [1, 2]. Barrett esophagus and esophageal
adenocarcinoma are both more common in men than in
women [1, 2]. The association of Barrett esophagus with
gastroesophageal reflux disease and with the develop-
ment of glandular dysplasia and esophageal adenocarcin-
oma has been firmly established [1–3].
Carbonic anhydrase 9 (CA9) is a transmembrane metal-
loenzyme that enzymatically catalyzes the reversible hydra-
tion of carbon dioxide to bicarbonate and protons [4–8].
CA9 expression is often upregulated in cancer cells in
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response to hypoxic-acidic environments [4–8]. CA9
expression has been associated with tumor acid–base
homeostasis under conditions of hypoxia, cancer pro-
gression, metastasis, and impaired response to trad-
itional therapy [4, 5, 9] and is found in many types of
cancer, including those of the kidney, bile duct, stom-
ach, esophagus, lung, breast, cervix, ovaries, bladder,
brain, head and neck, and oral cavity [4–15]. High expres-
sion of CA9 has been associated with poor prognosis
and poor response to conventional chemoradiation
therapy [4–15]. Inhibition of CA9 has been shown to
slow tumor growth, inhibit metastasis, and decrease
tumor stem cells in mice [16]. A few studies reported
that CA9 was highly expressed in esophageal adeno-
carcinoma and esophageal squamous cell carcinoma
[12, 14, 15, 17]. However, the percentages of expres-
sion of CA9 in these studies vary, and CA9 expression
in precancerous lesions has not been well studied.
CA9 expression was reported to be associated with
HIF-1α, Notch3, VHL and multiple genes in renal cell
carcinoma and/or breast carcinoma [18–20]. Muta-
tions of the common prolyl hydroxylation and pVHL
binding domain lead to the loss of CA9 mRNA, and
protein [19]. The BMI1 gene is a stem cell marker that
regulates proliferation [21] and has been observed in many
solid tumors [22–24]. High expression of BMI1 has also
been found in esophageal adenocarcinoma and esophageal
squamous cell carcinoma [25–27]. Since CA9 was recently
reported to play an important role in breast cancer
stem cell survival [28], we investigated the association of
BMI1 with CA9 in esophageal cancer. Cyclin E plays an
important role in promoting the G1- to S-phase transition
and is involved in several oncogenic functions [29, 30].
Amplification and overexpression of cyclin E have been
reported in various cancers [31–33]. Recently, we found
that the overexpression and amplification of cyclin E sig-
nificantly increased comparing nondysplastic esophageal
lesions to dysplastic lesions [34]. Since CA9 has been re-
ported to functionally mediate tumor growth and metas-
tasis [35], we investigated the relationship of CA9 and
cyclin E expression in esophageal cancer.
Minichromosome maintenance (MCM) protein fam-
ily consists of six related proteins that originally identi-
fied as having essential roles in initiation of DNA
replication [36, 37]. The deregulation of the MCM
proteins has been contributed to tumorigenesis and cell
proliferation [38] and may be pre-cancer markers [39].
The relationship of MCM proteins with CA9 is unknown
in esophageal lesions.
In current study, we first explored the relationship of
CA9 high expression with gastroesophageal reflux disease
including columnar cell metaplasia, Barrett’s esophagus,
low-and high-grade dysplasia. Second, we examined the as-
sociation of CA9 high expression with the clinicopathologic
characteristics of esophageal squamous cell carcinoma and
esophageal adenocarcinoma. Finally, we analyzed the
association of CA9 overexpression with BMI1, cyclin E,
MCM4, MCM7 and Ki67 expression in esophageal
adenocarcinoma.
Materials and methods
Tissue microarrays for current study
The tissue microarrays were constructed with samples
from 62 patients with squamous epithelium, 58 patients
with columnar cell metaplasia, 27 patients with Barrett
esophagus, 20 patients with low-grade dysplasia, 17 pa-
tients with high-grade dysplasia, 112 patients with
esophageal adenocarcinoma and 23 patients with squa-
mous cell carcinoma. Samples were collected from rep-
resentative areas of formalin-fixed specimens. Three
cores of each case were collected for the tissue micro-
array. All specimens were collected between 1997 and
2005, and the microarrays were constructed in the De-
partment of Pathology and Laboratory Medicine at The
University of Rochester Medical Center. We obtained
clinicopathologic data, including patient age and sex,
lymph node status, TNM stage, differentiation, and sur-
vival duration from the medical records. All patients’ iden-
tification was removed. This study is approved by The
University of Rochester Medical Center RSRB office.
For this study, 5 micron sections were cut from the
tissue microarrays and were stained with hematoxylin
and eosin to confirm the tissue histology of each tissue
core. Additional multiple sections were cut for immuno-
histochemical analysis. Four tissue cores were dislodged
from the slides during the processing and were excluded
from our study.
All 112 patients (99 men [88 %] and 13 women
[12 %]) with esophageal adenocarcinoma samples in-
cluded in the tissue microarray were treated with esoph-
agectomy at the Strong Memorial Hospital (University
of Rochester Medical Center; Rochester, NY) between
1997 and 2005. Patient age ranged from 34 to 85 years,
with a mean of 65 years. The follow-up period after
esophagectomy ranged from 0.3 to 142 months, with a
mean of 39 months. All other patient specimens were
collected at University of Rochester.
Immunohistochemical analysis
Immunohistochemical analysis was carried out accord-
ing to methods described previously, with some modifi-
cations [34, 40]. Briefly, tissue sections from the tissue
microarrays were deparaffinized, rehydrated with graded
alcohol, and washed with phosphate-buffered saline solu-
tion. Antigen retrieval for CA9, BMI1, cyclin E, MCM4,
MCM7 and Ki67 was performed by boiling tissue sections
in citrate buffer (pH 6.0; 10 mM) for 15 min. The tissues
were permeabilized with 0.3 % Triton X-100 for 1 h at
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room temperature. After endogenous peroxidase activity
was quenched and nonspecific binding was blocked, the
sections were incubated with mouse monoclonal anti-CA9
(1:200; Thermo Fisher Scientific Pierce, Rockford, IL), anti-
BMI1 (1:100; EMD Millipore, Billerica, MA), anti-cyclin E
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA), anti-
MCM4 (1:50; Santa Cruz, CA), anti-MCM7 (1:50; Santa
Cruz, CA) at 4 °C overnight, and anti-Ki67 (1:100; Santa
Cruz, CA) at room temperature for 20 min. The secondary
antibody (Flex HRP; Dako, Carpinteria, CA) was allowed to
incubate for 30 min. After washing, sections were incubated
with Flex DAB Chromogen (Dako, Carpinteria, CA)
for 10 min and counterstained with Flex Hematoxylin
for 5 min. Negative controls were obtained by replacing
antibodies with normal serum.
All sections were reviewed independently by Z.Z. and
A.R.H. Both pathologists were blinded to all clinical and
pathologic information. Discrepancies were reviewed by
both Z.Z. and A.R.H., and a final consensus was reached.
The percentage (0 %–100 %) of cells that stained positive
was determined. The intensity of CA9, BMI1 and cyclin
E staining was graded as follows: 0, no stain or weak
stain in < 10 % cells; 1, weak stain in ≥ 10 % tumor cells; 2,
moderate stain in ≥ 10 % cells; or 3, strong stain in ≥
10 % cells (Fig. 1). CA9, BMI1, and cyclin E protein
expression was considered high if 10 % or more of cells
stained with an intensity score of 2 or 3 (Fig. 1). The inten-
sity of MCM4, MCM7, and Ki67 immunostaining was
graded as 0 (negative) or 1+ (positive). The percentage of
cells with positive nuclear immunostaining, ranging from 0
to 100 % was recorded in the increments of 10.
Statistical analysis
Summary data are expressed as means ± standard devi-
ations (SD) for continuous variables and as percent-
ages for categorical variables. All statistical tests were
2-sided. P values less than 0.05 were considered statis-
tically significant. Kaplan-Meier survival analysis and
the log-rank test were used to analyze overall survival
between the high CA9 expression group and the low
CA9 expression group in esophageal adenocarcinoma.
To assess the association of the clinicopathologic
characteristics with CA9 expression, we used t-tests,
Pearson chi-square tests, and Fisher exact tests as ap-
propriate. A univariate logistic model with the histo-
logic group as the sole explanatory variable of high
CA9 expression was used, and contrast tests were
used to compare the rates of high CA9 expression
among the histologic groups. Statistical analyses were
performed using SAS software, version 9.3 (SAS Institute,
Inc., Cary, NC).
Fig. 1 Intensity of carbonic anhydrase IX (CA9) expression in esophageal adenocarcinoma with immunohistochemical staining. Samples were scored from
0 to 3: a, Negative (0, no stain or weak stain in <10 % cells). b, Weakly positive (1, weak stain in≥ 10 % cells). c, Moderately positive (2, moderate stain in≥
10 % cells). d, strongly positive (3, strong stain in≥ 10 % cells). CA9 expression was predominantly distributed in the tumor cell membrane
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Results
High CA9 expression in esophageal adenocarcinoma and
precancerous lesions
Immunostaining results showed that CA9 was predom-
inantly expressed in the cell membrane and rarely in the
cytoplasm (Fig. 1). Of the tissue microarray cases, 90 %
(101/112) esophageal adenocarcinoma, 94 % (16/17)
high-grade dysplasia, 85 % (17/20) low-grade dysplasia,
74 % (20/27) Barrett esophagus, 83 % (48/58) columnar
cell metaplasia, 9 % (2/23) squamous cell carcinoma,
and 0 % (0/62) squamous epithelium had high CA9 ex-
pression (Table 1, Fig. 1, 2 and 3). The rate of high CA9
expression in patients with squamous cell carcinoma or
squamous epithelium was significantly lower than that
in patients with esophageal adenocarcinoma, high-grade
dysplasia, low-grade dysplasia, Barrett esophagus, or col-
umnar cell metaplasia (Table 2). High CA9 expression
occurred predominantly in columnar cell lesions but was
rare or absent in squamous cell carcinoma and squa-
mous epithelium (Fig. 2).
Association of high CA9 expression with clinicopathologic
characteristics in esophageal cancer
We intended to analyze the association of high CA9
expression with clinicopathologic features in the esopha-
geal adenocarcinoma and squamous cell carcinoma
groups. Because only 1 patient with squamous cell car-
cinoma had high CA9 expression (1/23), we could not
evaluate the association of CA9 expression with clinico-
pathologic characteristics for the squamous cell carcin-
oma group. None of the clinicopathologic characteristics
were significantly associated with intensity of CA9 expres-
sion in the esophageal adenocarcinoma group (Table 3).
In esophageal adenocarcinoma and precancerous tis-
sue groups, the patients with the high CA9 expression
are 188 in male and 19 in female; the patients with the
low or no CA9 expression are 89 in male and 29 in
female. The overall association of high CA9 expression
with male sex was significant (P = .0011). The odds of
high CA9 expression were 2.8 times higher in men than
in women.
Overall survival analysis
We analyzed the effect of high CA9 expression on over-
all survival in patients with esophageal adenocarcinoma
or squamous cell carcinoma. However, we could not ob-
tain mean or median survival duration for patients with
high CA9 expression in the squamous cell carcinoma
group since only 1 of these patients showed high CA9
expression. The median survival duration of patients in
this group with low CA9 expression was 26 months,
with a mean survival of 37 months.
The median survival duration for patients with
esophageal adenocarcinoma in the high CA9 expression
group was 20 months, with a mean survival of 40
months. The patients with low CA9 expression had a
median survival of 20 months, with a mean survival of
41 months. The survival duration did not significantly
differ between patients with high CA9 expression and
low CA9 expression (P = .8488).
High CA9 expression is associated with multiple markers
including BMI1, cyclin E, MCM4, MCM7 and Ki67
The rate of high CA9 expression was statistically associ-
ated with BMI1, cyclin E high expression and MCM4,
MCM7 and Ki67 expression (P < .001) with Pearson correl-
ation method. The correlation coefficient is positive related
between CA9 expression with cyclin E (r = .1425),
Ki67 (r = .1288), BMI1 (r = .2852), MCM4 (r = .2946)
and MCM7 (r = .3106).
Discussion
High CA9 expression was present in most glandular le-
sions but occurred rarely in squamous cell carcinoma;
squamous epithelium did not show high CA9 expres-
sion. High CA9 expression maybe not significantly asso-
ciated with the progression of precancerous esophageal
disease to esophageal adenocarcinoma since the high
CA9 expression did not show significant difference
among all glandular lesions. However, high CA9 expres-
sion was significantly more frequent in glandular lesions
than in squamous epithelium (0 %) and squamous cell
carcinoma (9 %). CA9 could be a unique marker to dif-
ferentiate adenocarcinoma and squamous cell carcinoma
in poorly differentiated esophageal cancer.
The high CA9 expression in esophageal glandular
lesions could be related to the hypoxic-acidic environment
and columnar cell survival. Gastroesophageal reflux disease
is a major risk factor for columnar cell metaplasia, Barrett
esophagus, low- and high-grade dysplasia, and esophageal
adenocarcinoma. Acid reflux from the stomach damages
the cell junctions and causes dilation of the intercellular
space; this acidic environment in the gastroesophageal
Table 1 Rate of high carbonic anhydrase IX (CA9) expression in
each histologic group
Histologic type Total (n) High expression Low expression
N (%) N (%)
Adenocarcinoma 112 101 (90 %) 11 (10 %)
High-grade dysplasia 17 16 (94 %) 1 (6 %)
Low-grade dysplasia 20 17 (85 %) 3 (15 %)
Barrett esophagus 27 20 (74 %) 7 (26 %)
Columnar cell metaplasia 58 48 (83 %) 10 (17 %)
Squamous cell carcinoma 23 2 (9 %) 21 (91 %)
Squamous epithelium 62 0 (0 %) 62 (100 %)
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Fig. 2 Squamous epithelium and esophageal squamous cell carcinoma samples showed no high intensity of carbonic anhydrase IX (CA9) expression.
a. Squamous epithelium with H&E stain; b. No high CA9 expression in squamous epithelium; c. Squamous cell carcinoma with H&E stain; d. No high CA9
expression in sqaumous cell carcinoma
Fig. 3 High carbonic anhydrase IX (CA9) expression in precancerous lesions. The samples showed strongly positive staining predominantly in the cell
membrane. a, Columnar cell metaplasia (score 3). b, Barrett esophagus (score 3). c, Low-grade dysplasia (score 3) d, High-grade dysplasia (score 3)
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junction and distal esophagus damages squamous epithe-
lium and causes columnar cell metaplasia. CA9 is a well-
known hypoxic indicator and plays an important role in
maintaining the intracellular pH despite increased extracel-
lular acidosis [17], thereby promoting cancer cell survival
and growth in hypoxic-acidic environments. High levels of
CA9 in columnar cell metaplasia and other precancerous
glandular lesions may protect glandular cell survival in the
acidic environment induced by gastroesophageal reflux dis-
ease. Therefore, most of the glandular tissues in our study
showed high CA9 expression, with no significant difference
between groups. In contrast, the very low frequency of high
expression of CA9 in normal squamous epithelium and
squamous cell carcinoma may be attributable to these tis-
sues’ non-involvement by acid reflux.
The reported expression of CA9 in esophageal adeno-
carcinoma has varied from 47 to 80 % [12, 14, 17].
Conflicting results, ranging from 0 to 100 %, have also
been published for CA9 expression in gastric adenocar-
cinoma [41–43]. In our study, the rate of high CA9
expression was very high in esophageal adenocarcinoma
(90 %) and precancerous lesions (74 %–94 %) but was
very low in esophageal squamous cell carcinoma (9 %).
Several studies showed high CA9 expression in esopha-
geal squamous cell carcinoma, ranging from 41 to 100 %
[11, 14, 17]. Tanaka et al. found high expression of CA9
in 63 of 127 squamous cell carcinoma samples (50 %) [11].
However, there was a discrepancy in their results; the
squamous cell carcinoma tissues seemed to have high
CA9 expression, but this intensity of CA9 high expres-
sion in their figure was lower than that of the positive
control (columnar cell metaplasia). Our findings show
that patients with squamous cell carcinoma had low or
Table 2 Comparison of high carbonic anhydrase IX (CA9)
expression rates among histologic groups
Histologic comparison P value
Adenocarcinoma vs.
Barrett esophagus .0312
Columnar cell metaplasia .1683
High-grade dysplasia .6066
Low-grade dysplasia .4918
Squamous cell carcinoma < .0001**
Squamous epithelium < .0001**
Barrett esophagus vs.
Columnar cell metaplasia .3543
High-grade dysplasia .1241
Low-grade dysplasia .3706
Squamous cell carcinoma .0002**
Squamous epithelium < .0001**
Columnar cell metaplasia vs.
High-grade dysplasia .2684
Low-grade dysplasia .8167
Squamous cell carcinoma < .0001**
Squamous epithelium < .0001**
High-grade dysplasia vs.
Low-grade dysplasia .3894
Squamous cell carcinoma < .0001**
Squamous epithelium < .0001**
Low-grade dysplasia vs.
Squamous cell carcinoma <.0001**
Squamous epithelium <.0001**
Squamous cell carcinoma vs. .4776
Squamous epithelium .4776
**Indicates significance using the Bonferroni correction with α= 0.05/21 (0.00238)
Table 3 Relationship of high carbonic anhydrase IX (CA9)
expression and clinicopathologic characteristics in the esophageal







Mean (SD) 64.8 (10.8) 63.5 (12.0) .7260
Range (34–85) (36–80)
Sex
Male 89 10 .7598
Female 12 1
Lymph node metastasis
Positive nodes 3.7 (4.5) 3.9 (6.5) .8752
T Stage














Poor 68 5 .3196
Moderate 32 4
Well 5 1
TNM Tumor Staging based on WHO Classification of Malignant Tumors; N stage
based on lymph node metastasis
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no CA9 expression. The discrepancy between our find-
ings and those of Tanaka et al. could be explained by
the difference in our criteria for high expression. The
antibodies and methods used in these esophageal can-
cer studies were also different. In addition, locations or
races are different in all these studies. Therefore, the
different percentages of CA9 high expression may be
related with multiple factors including races, locations,
antibodies and methods.
Several factors, such as the antibodies, the grading cri-
teria, cancer heterogeneity, or immunostaining proto-
cols, could explain these conflicting results about CA9
expression. We used the intensity of CA9 expression in
glandular cells as the standard intensity. Our criterion
for high CA9 expression was 10 % or more cells with an
intensity score of 2 or 3. With our standard, the squa-
mous cell carcinoma samples had low or no CA9 ex-
pression. Additionally, we used tissue microarrays for
the immunohistochemical analysis: all tissue samples
were automatically processed in the same conditions
and at the same time in our pathologic laboratory. It is
not possible that the lower intensity of squamous epithe-
lium and squamous cell carcinoma was due to the
immunohistological method variations.
Many studies have shown that CA9 high expression is
associated with worse prognosis in solid tumors than
lower or no CA9 expression in them [11, 12, 17]. How-
ever, in our study, high CA9 expression was not associ-
ated with worse prognosis, which may be due to the
very high percentage of esophageal adenocarcinoma
samples with high CA9 expression (90 %). Only a few
cases (11/112; 10 %) did not show CA9 high expression.
Additionally, the high CA9 expression was not associ-
ated with clinicopathologic features such as age, lymph
node metastasis, tumor stage, and prognosis but was sig-
nificantly associated with male sex (P = .0011). Men also
have a higher risk for esophageal adenocarcinoma than
women (men: women, 7–10:1). Our finding of the sig-
nificant association of high CA9 expression with male
sex implies that CA9 could be associated with men’s
higher risk for esophageal adenocarcinoma.
Inhibition of CA9 with sulfonamide and/or coumarin
inhibitors was recently shown to lead to a potent retard-
ation for the growth of both primary tumors and metasta-
ses [44]. In addition, RENCAREX, a cG250 antibody (one
of specific anti CA9 antibodies) underwent phase I-III
clinical trials for treatment of patients with RCC.
Phase I-II showed promising effects on metastatic
renal cell carcinoma patients’ survival rate and toler-
ance of the antibody [45]. High CA9 expression in
esophageal adenocarcinoma suggests that CA9 could
be a therapeutic target in this cancer.
High CA9 expression was significantly associated with
high BMI1 expression in esophageal adenocarcinoma
and precancerous lesions. In our previous studies, the
percentage and intensity of BMI1 expression signifi-
cantly increased during the progression from columnar
cell metaplasia to Barrett esophagus, low- and high-
grade dysplasia, and adenocarcinoma [25]. We previ-
ously found that cells with high BMI1 expression had
different distribution patterns in different types of tissue:
mostly within the bottom of metaplastic columnar cell
tissue compared with the full-gland distribution in dyspla-
sia and adenocarcinoma. BMI1 is a stem cell marker that
regulates self-renewal and differentiation; BMI1 also plays
a role in cell-cycle regulation and carcinogenesis [46]. A
recent study reported that CA9 plays an important role in
the expression of epithelial-mesenchymal transition in
breast cancer and is a critical mediator of the expansion of
breast cancer stem cells [28]. CA9-specific small molecule
inhibitors restricted the expansion of cancer stem cells.
Our findings of the significant association of high CA9 ex-
pression with BMI1 imply that CA9 may be involved in
esophageal tumorigenesis through esophageal stem cells.
High CA9 expression was significantly associated with
cyclin E expression in esophageal adenocarcinoma and
precancerous lesions. However, the correlation was low
(r = .1425). Because CA9 maintains intracellular pH
and helps tumor cells survive in hypoxic-acidic envi-
ronments, CA9 may not be directly associated with
cyclin E, which helps regulate the cell cycle.
High CA9 expression was significantly associated with
MCM4, MCM7 and Ki67 expression in esophageal
adenocarcinoma and precancerous lesions. However, the
correlation was low (r = .1388) with Ki67 and relative
higher (r = .2946; r = .3106) with MCM4 and MCM7.
MCM4 and MCM7 are the part of MCM protein family,
which play an essential roles in initiation of DNA repli-
cation [36, 37] and may be pre-cancer markers [39]. The
deregulation of the MCM proteins has been contributed
to tumorigenesis and cell proliferation [38]. The correl-
ation of high CA9 expression with MCM4 and MCM7
in precancerous lesions implies that CA9 may play a role
of tumorigenesis in the early stage. Ki67 is a traditional
proliferation marker. The lower correlation of high CA9
expression with Ki67 indicates that CA9 may not be dir-
ectly associated with cell proliferation.
Conclusion
High CA9 expression may be related to the acidic envir-
onment in the gastroesophageal junction caused by gas-
troesophageal reflux disease. We found that high CA9
expression was associated with BMI1, MCM4 and
MCM7, which indicate that CA9 may play a role in early
tumorigenesis. CA9 was not a significant prognostic
marker in patients with esophageal adenocarcinoma but
may be associated with men’s high risk for esophageal
adenocarcinoma. Its high expression in esophageal
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adenocarcinoma suggests that CA9 could be a therapeutic
target in this cancer.
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